Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:1319
Name brain cancer
Definition A central nervous system cancer that is characterized by the growth of abnormal cells in the tissues of the brain.
Source DiseaseOntology.org
Alt Ids DOID:2125 DOID:3543 DOID:911 DOID:6649 DOID:2126
Path disease disease of cellular proliferation cancer organ system cancer nervous system cancer central nervous system cancer brain cancer


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01386580 Phase Ib/II 2B3-101 2B3-101 + Trastuzumab An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. Completed USA | NLD | FRA | BEL 0
NCT01518413 Phase I Irinotecan + Sorafenib Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors Completed USA 0
NCT01753713 Phase II Dovitinib Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma Completed USA 0
NCT02015728 Phase I Erlotinib Everolimus Dasatinib Etoposide + Temozolomide Sorafenib Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors Unknown status USA 0
NCT02130869 Phase I Bendamustine + Cytarabine + Etoposide Busulfan + Hu14.18K322A Aldesleukin + Melphalan + Sargramostim Filgrastim Carboplatin + Etoposide A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas Completed USA 0
NCT02502708 Phase I Indoximod Temozolomide Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors Completed USA 0
NCT02574728 Phase II Celecoxib + Cyclophosphamide + Etoposide + Sirolimus Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors Recruiting USA 0
NCT02644291 Phase I Mebendazole Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors Completed USA 0
NCT02644460 Phase I Abemaciclib Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors Completed USA 0
NCT02698254 Phase 0 Bevacizumab Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy Active, not recruiting USA 0
NCT02925234 Phase II Crizotinib Sunitinib Niraparib Olaparib Lorlatinib Erdafitinib Talazoparib Dacomitinib Axitinib Panitumumab The Drug Rediscovery Protocol (DRUP Trial) (DRUP) Recruiting NLD 0
NCT03068832 Phase I Poly ICLC Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors Withdrawn 0
NCT03330197 Phase I Ad-RTS-IL-12 plus AL A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors or DIPG Terminated USA 0
NCT03434262 Phase I Ribociclib + Trametinib Filgrastim + Gemcitabine + Ribociclib Ribociclib + Sonidegib SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Completed USA 0
NCT03478462 Phase I CLR 131 Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma Active, not recruiting USA | CAN | AUS 0
NCT03510208 Phase Ib/II Panitumumab Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery Recruiting USA 0
NCT03668847 Phase II DM-CHOC-PEN DM-CHOC-PEN for Brain Tumors in AYA Subjects Completed USA 0
NCT03967093 Phase I BXQ-350 A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors Terminated USA 0
NCT04334863 Phase I WP1066 AflacST1901: Peds WP1066 Completed USA 0
NCT04430842 Phase I QBS10072S Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S Completed AUS 0
NCT04525014 Phase I Irinotecan + RRx-001 + Temozolomide RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors (PIRATE) Active, not recruiting USA 0
NCT04543188 Phase I Binimetinib + Midazolam + PF-07284890 Binimetinib + PF-07284890 PF-07284890 A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement Terminated USA | CAN 1
NCT04579380 Phase II Trastuzumab + Tucatinib Fulvestrant + Trastuzumab + Tucatinib Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations Active, not recruiting USA | NLD | ITA | GBR | ESP | DEU | BEL 3
NCT04732065 Phase I ONC206 ONC206 for Treatment of Newly Diagnosed or Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant Brain Tumors (PNOC 023) Recruiting USA 1
NCT05169944 Phase I Hu5F9-G4 Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors (PNOC025) Suspended USA 0
NCT06058988 Phase II Trastuzumab deruxtecan Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Recruiting USA 0